{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:59:15Z","timestamp":1790222355573,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T00:00:00Z","timestamp":1383091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T00:00:00Z","timestamp":1383091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The objective of the study was to investigate the impact of newer biologic treatments including rituximab, abatacept and tocilizumab on antibody response following pneumococcal vaccination using a 7-valent conjugate vaccine in patients with established rheumatoid arthritis (RA).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Patients with RA receiving rituximab, abatacept or tocilizumab as monotherapy or combined with methotrexate (MTX) participated in the study. Specific IgG antibodies against 23F and 6B serotypes were measured at vaccination and 4 to 6\u00a0weeks after vaccination using standardised ELISA. Geometric mean antibody levels (GML) were calculated. Antibody response (AR) was defined as the ratio between post- and pre-vaccination antibody levels and a positive antibody response (posAR) was AR \u22652.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>In total, 88 patients were enrolled in the study. Of 55 patients treated with rituximab, 26 (46%) were on concomitant MTX. Of patients receiving abatacept (n\u2009=\u200917) and tocilizumab (n\u2009=\u200916) biologic treatment was given in combination with MTX in 13 (76%) and 9 (56%) patients, respectively. Patients treated with rituximab had significantly lower AR compared to those on tocilizumab, as well as compared to previously reported RA patients on MTX and controls (spondylarthropathy patients treated with NSAIDs and\/or analgesics). In total, 10.3% of patients on rituximab monotherapy and no patient on rituximab\u2009+\u2009MTX had posAR for both serotypes. For abatacept and tocilizumab the corresponding figures were 17.6% and 50%.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>In this cohort of patients with established RA, treatment with rituximab and abatacept was associated with diminished antibody response but this was most pronounced for rituximab. Pneumococcal conjugate vaccine administrated during ongoing tocilizumab treatment seems to be associated with sufficient antibody response. Pneumococcal vaccination should preferably be encouraged before initiation of rituximab or abatacept treatment.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/NCT00828997?term=NCT00828997&amp;rank=1\">NCT00828997<\/jats:ext-link> and EudraCT EU<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-006539-29\">2007-006539-29<\/jats:ext-link>.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4358","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T03:09:04Z","timestamp":1383102544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":125,"title":["Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis"],"prefix":"10.1186","volume":"15","author":[{"given":"Meliha","family":"Crnkic Kapetanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Saxne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Truedsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Geborek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,30]]},"reference":[{"key":"4433_CR1","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","volume":"294","author":"CA Lexau","year":"2005","unstructured":"Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG: Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005, 294: 2043-2051. 10.1001\/jama.294.16.2043.","journal-title":"JAMA"},{"key":"4433_CR2","first-page":"40","volume":"61","author":"CDC. Advisory Committee on Immunization Practices","year":"2012","unstructured":"CDC. Advisory Committee on Immunization Practices: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2012, 61: 40-[http:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/adult.html]","journal-title":"MMWR"},{"key":"4433_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2010.137216","volume":"70","author":"S van Assen","year":"2011","unstructured":"van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, M\u00fcller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011, 70: 414-422. 10.1136\/ard.2010.137216.","journal-title":"Ann Rheum Dis"},{"key":"4433_CR4","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1002\/art.30580","volume":"63","author":"MC Kapetanovic","year":"2011","unstructured":"Kapetanovic MC, Roseman C, J\u00f6nsson G, Truedsson L, Saxne T, Geborek P: Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011, 63: 3723-3732. 10.1002\/art.30580.","journal-title":"Arthritis Rheum"},{"key":"4433_CR5","unstructured":"EudraCT: [https:\/\/eudract.ema.europa.eu]"},{"key":"4433_CR6","first-page":"514","volume":"10","author":"CM Wernette","year":"2003","unstructured":"Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, K\u00e4yhty H, Jonsdottir I, Nahm MH: Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003, 10: 514-519.","journal-title":"Clin Diagn Lab Immunol"},{"key":"4433_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"4433_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.25039","volume":"62","author":"EW St Clair","year":"2010","unstructured":"St Clair EW: Good and bad memories following rituximab therapy. Arthritis Rheum. 2010, 62: 1-5.","journal-title":"Arthritis Rheum"},{"key":"4433_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S van Assen","year":"2010","unstructured":"van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, Voskuyl A, de Haan A, Westra J, Kallenberg CG, Bijl M: Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010, 62: 75-81. 10.1002\/art.25033.","journal-title":"Arthritis Rheum"},{"key":"4433_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"CO Bingham 3rd","year":"2010","unstructured":"Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A: Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010, 62: 64-74. 10.1002\/art.25034.","journal-title":"Arthritis Rheum"},{"key":"4433_CR11","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F: Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open label extension analysis. Arthritis Rheum. 2007, 56: 3896-3908. 10.1002\/art.23059.","journal-title":"Arthritis Rheum"},{"key":"4433_CR12","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/ar2174","volume":"9","author":"L Tay","year":"2007","unstructured":"Tay L, Leon F, Vratsanos G, Raymond R, Corbo M: Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther. 2007, 9: R38-10.1186\/ar2174.","journal-title":"Arthritis Res Ther"},{"key":"4433_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/acr.21838","volume":"65","author":"AC Ribeiro","year":"2013","unstructured":"Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, Bonfa E: Abatacept severely reduces the immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013, 65: 476-480. 10.1002\/acr.21838.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4433_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/rheumatology\/kei193","volume":"45","author":"MC Kapetanovic","year":"2006","unstructured":"Kapetanovic MC, Saxne T, Sj\u00f6holm A, Truedsson L, J\u00f6nsson G, Geborek P: Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006, 45: 106-111. 10.1093\/rheumatology\/kei193.","journal-title":"Rheumatology (Oxford)"},{"key":"4433_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1172\/JCI117394","volume":"94","author":"AP Cope","year":"1994","unstructured":"Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994, 94: 749-760. 10.1172\/JCI117394.","journal-title":"J Clin Invest"},{"key":"4433_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1084\/jem.167.2.332","volume":"167","author":"A Muraguchi","year":"1988","unstructured":"Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T: The essential role of B cell stimulatory factor (BSF-2\/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988, 167: 332-344. 10.1084\/jem.167.2.332.","journal-title":"J Exp Med"},{"key":"4433_CR17","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1136\/annrheumdis-2012-201950","volume":"71","author":"S Mori","year":"2012","unstructured":"Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K: Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012, 71: 2006-2010. 10.1136\/annrheumdis-2012-201950.","journal-title":"Ann Rheum Dis"},{"key":"4433_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/eji.1830230436","volume":"23","author":"KE Costelloe","year":"1993","unstructured":"Costelloe KE, Smith SH, Callard RE: Interleukin 6 is not required for antigen-specific antibody responses by human B cells. Eur J Immunol. 1993, 23: 984-987. 10.1002\/eji.1830230436.","journal-title":"Eur J Immunol"},{"key":"4433_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"S Plotkin","year":"2010","unstructured":"Plotkin S: Correlates of protection induced by vaccination. Minireview. Clin Vaccine Immunol. 2010, 17: 1055-1065. 10.1128\/CVI.00131-10.","journal-title":"Clin Vaccine Immunol"},{"key":"4433_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1086\/323339","volume":"184","author":"B Henriques Normark","year":"2001","unstructured":"Henriques Normark B, Kalin M, Ortqvist A, Akerlund T, Olsson Liljeqvist B, Hedlund J: Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J Infect Dis. 2001, 184: 861-869. 10.1086\/323339.","journal-title":"J Infect Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4358\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4358.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:57:04Z","timestamp":1728385024000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,30]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,10]]}},"alternative-id":["4433"],"URL":"https:\/\/doi.org\/10.1186\/ar4358","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,30]]},"assertion":[{"value":"22 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R171"}}